首页 > 最新文献

Journal of Diabetes Investigation最新文献

英文 中文
Successful introduction of sensor-augmented pump therapy in a patient with diabetes and needle phobia: A case report 在糖尿病和针头恐惧症患者中成功引入传感器增强泵治疗:一例报告。
IF 3.2 3区 医学 Pub Date : 2023-07-26 DOI: 10.1111/jdi.14061
Keiji Sugai, Junpei Shikuma, Satoshi Hiroike, Hironori Abe, Ryo Suzuki

Needle phobia is a specific phobia classified as an anxiety disorder in the Diagnostic and Statistical Manual of Mental Disorders-5, and can be a serious problem for patients requiring insulin injections. However, there have been few reports to date on the management of adults with diabetes and needle phobia. We here report a case of a woman with pancreatic diabetes who developed needle phobia and could no longer perform self-injections. She started to use a sensor-augmented pump (SAP), and was able to perform a puncture for the insulin pump and the continuous glucose monitoring sensor by herself. The SAP treatment achieved self-management, better glycemic control, and high treatment satisfaction quantified using the Diabetes Treatment Satisfaction Questionnaire in this patient. Our case suggests the therapeutic potential of SAP in adults with needle phobia and diabetes requiring insulin therapy.

针头恐惧症是一种特殊的恐惧症,在《精神疾病诊断和统计手册》-5中被归类为焦虑症,对于需要注射胰岛素的患者来说,这可能是一个严重的问题。然而,迄今为止,关于糖尿病和针头恐惧症成年人的治疗报告很少。我们在此报告一例患有胰腺糖尿病的女性,她出现了针头恐惧症,无法再进行自我注射。她开始使用传感器增强泵(SAP),并能够自己为胰岛素泵和连续血糖监测传感器进行穿刺。SAP治疗实现了该患者的自我管理、更好的血糖控制和使用糖尿病治疗满意度问卷量化的高治疗满意度。我们的病例表明SAP在需要胰岛素治疗的成人针头恐惧症和糖尿病患者中具有治疗潜力。
{"title":"Successful introduction of sensor-augmented pump therapy in a patient with diabetes and needle phobia: A case report","authors":"Keiji Sugai,&nbsp;Junpei Shikuma,&nbsp;Satoshi Hiroike,&nbsp;Hironori Abe,&nbsp;Ryo Suzuki","doi":"10.1111/jdi.14061","DOIUrl":"10.1111/jdi.14061","url":null,"abstract":"<p>Needle phobia is a specific phobia classified as an anxiety disorder in the Diagnostic and Statistical Manual of Mental Disorders-5, and can be a serious problem for patients requiring insulin injections. However, there have been few reports to date on the management of adults with diabetes and needle phobia. We here report a case of a woman with pancreatic diabetes who developed needle phobia and could no longer perform self-injections. She started to use a sensor-augmented pump (SAP), and was able to perform a puncture for the insulin pump and the continuous glucose monitoring sensor by herself. The SAP treatment achieved self-management, better glycemic control, and high treatment satisfaction quantified using the Diabetes Treatment Satisfaction Questionnaire in this patient. Our case suggests the therapeutic potential of SAP in adults with needle phobia and diabetes requiring insulin therapy.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 11","pages":"1318-1320"},"PeriodicalIF":3.2,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Delineating the transcriptional atlas for impaired insulin secretion: A window into type 2 diabetes pathophysiology 描绘胰岛素分泌受损的转录图谱:进入类型的窗口 2糖尿病病理生理学。
IF 3.2 3区 医学 Pub Date : 2023-07-26 DOI: 10.1111/jdi.14060
Jian Li, Jin Yang, Tianpei Hong

Impaired insulin secretion from pancreatic islet β-cells is a major cause of metabolic dysregulation and type 2 diabetes mellitus. Complete transcriptomic characterization of islets in patients with type 2 diabetes mellitus has yet to be completed, and it remains challenging to link insulin secretion dysfunction with precise changes in gene expression. There are several ongoing initiatives aimed at enabling the discovery of regulatory molecules that might contribute to insulin secretion dysfunction and whole-body glucose homeostasis impairment. In one such line of research, Bacos et al.1 obtained evidence suggesting that the gene PAX5 might play an important role in impaired insulin secretion in human islets (Figure 1).

Given the established differences between mouse and human islets, type 2 diabetes mellitus candidate genes that were identified in mice might not have the same regulative effects on human islets. There is an unmet need for powerful transcriptomic analyses that can be applied to human islets isolated from individuals with type 2 diabetes mellitus and nondiabetic controls. Due to the difficulties associated with obtaining human islets, most human islet transcriptomic studies thus far have involved small cohorts and have lacked functional validation. Bacos et al.1 generated a ribonucleic acid sequencing (RNA-Seq) resource bank from the large Lund University Diabetes Center pancreatic islet cohort. It is one of the largest existing type 2 diabetes mellitus human islet cohorts in existence, providing an extensive gene expression resource based on 309 islet preparations in total from individuals with type 2 diabetes mellitus and nondiabetic controls. They then identified 395 differentially expressed genes (DEGs) from the Lund University Diabetes Center cohort, and further performed some functional validation of DEGs in vitro.

The utility of transcriptomic resources can be affirmed by robust replication of DEGs across studies and databases. To date, few DEG replication studies in type 2 diabetes mellitus human islets have been reported, and the various studies in the literature showing replication have been relatively small, including the work by Bacos et al.1 Unsurprisingly, the variance in demographic and pathophysiological profiles among sample donors affects DEG overlap across study cohorts. There remains a need to analyze human islets from a more diverse donor pool, and larger cohorts to clarify whether islet gene expression differs among individuals with type 2 diabetes mellitus in relation to demographic and pathophysiological variables. Another important factor affecting DEG overlap is the particular screen technology applied. RNA-Seq, microarray analysis and other screening technologies have been used to identify genes with altered expression in type 2 diabetes mellitus human islets, generating transcriptiona

胰岛β细胞胰岛素分泌受损是代谢失调和2型糖尿病的主要原因。2型糖尿病患者胰岛的完整转录组学特征尚未完成,将胰岛素分泌功能障碍与基因表达的精确变化联系起来仍然具有挑战性。有几个正在进行的项目旨在发现可能导致胰岛素分泌功能障碍和全身葡萄糖稳态损害的调节分子。在其中一项研究中,Bacos等人。我获得的证据表明,基因PAX5可能在人胰岛胰岛素分泌受损中发挥重要作用(图1)。鉴于小鼠和人胰岛之间已确定的差异,在小鼠中发现的2型糖尿病候选基因可能对人胰岛没有相同的调节作用。对于从2型糖尿病患者和非糖尿病对照组中分离的胰岛进行强大的转录组学分析的需求尚未得到满足。由于获取人类胰岛的困难,迄今为止大多数人类胰岛转录组学研究都涉及小群体,缺乏功能验证。Bacos等人。1从隆德大学糖尿病中心的大型胰岛队列中生成了核糖核酸测序(RNA-Seq)资源库。它是现有最大的2型糖尿病人胰岛队列之一,提供了基于309种胰岛制剂的广泛基因表达资源,这些制剂来自2型糖尿病患者和非糖尿病对照组。然后,他们从隆德大学糖尿病中心的队列中鉴定了395个差异表达基因(deg),并进一步在体外对deg进行了一些功能验证。转录组学资源的效用可以通过在研究和数据库中可靠地复制deg来证实。迄今为止,在2型糖尿病人胰岛中很少有DEG复制研究的报道,并且文献中显示复制的各种研究相对较少,包括Bacos等人的工作1不出所料,样本供体中人口统计学和病理生理特征的差异会影响研究队列中DEG的重叠。仍然需要分析来自更多样化的供体池和更大的队列的人类胰岛,以澄清胰岛基因表达在2型糖尿病患者中是否与人口统计学和病理生理变量有关。影响DEG重叠的另一个重要因素是所采用的特定筛分技术。RNA-Seq、微阵列分析等筛选技术已被用于鉴定2型糖尿病人胰岛中表达改变的基因,产生具有不同敏感性和特征可靠性的转录资源。最先进的RNA-Seq技术继续提高我们对2型糖尿病人胰岛转录图谱的理解,如Bacos等人的论文所示值得注意的是,先前的研究提供了明确的证据,表明相对于非糖尿病胰岛,2型糖尿病改变了人类胰岛的细胞组成。单细胞RNA-Seq可以根据细胞类型对细胞进行分类,从而实现细胞类型解析分析,从而可以在单细胞分辨率水平上检查转录变异,从而有可能规避澄清2型糖尿病相关deg的挑战。Camunas-Soler等人在一项研究中纳入了34名患有和不患有糖尿病的人类供体的胰腺。2表明单细胞RNA-Seq可以与胞外分泌和通道活性的电生理测量相结合,将内分泌生理学与单细胞水平上的转录组学数据联系起来。此外,最近开发的一种称为空间转录组测序的方法可以同时获得关于胰岛细胞的空间位置和基因表达的信息。这种创新可以作为一种重要的筛选工具,对基因及其微环境之间的相互作用敏感。验证观察到的人类胰岛转录组变化是否与胰岛素分泌受损有功能联系是必要的。Bacos等人的分析。在隆德大学糖尿病中心的一项研究中,未被诊断为2型糖尿病的个体中,三分之一的已确定的deg的表达与HbA1c水平呈线性相关。这些结果表明,这些基因表达的变化可能先于2型糖尿病的诊断,并可能有助于2型糖尿病的发展。DEG结果取决于分层的hba1c水平范围标准的严格程度。 因此,Bacos等人研究中的一小部分个体。1例根据HbA1c水平42 mmol/mol(6.0%)未被认为患有2型糖尿病的患者可能为糖尿病前期。事实上,生物信息学、遗传学和表观遗传学分析表明Bacos等人在研究中发现的几个deg。1 .染色质状态或脱氧核糖核酸甲基化发生改变;与这些deg相关的单核苷酸多态性可能影响2型糖尿病的病因和2型糖尿病相关的代谢特征。对公共啮齿动物体内数据集的分析(见国际小鼠表型联盟)表明,缺乏某些DEGs的小鼠品系会损害葡萄糖稳态并改变身体成分。然而,这些小鼠的代谢缺陷是否由于胰岛和/或外周影响,应该澄清。上述分析表明Bacos等人鉴定的许多deg。1可能与胰岛素分泌功能障碍有关,但这种可能性需要直接证据。通常需要功能基因组方法来测试DEG对胰岛素分泌的影响,其中通过模拟人类胰岛中2型糖尿病相关的DEG变化来探索修改相关基因表达的影响。在Bacos等人研究的11个顶级和/或关键deg中,选择1个进行功能验证,6个被证实与胰岛素分泌紊乱有功能关系,包括3个表达升高的deg (PAX5、NEFL和PCOLCE2)和3个表达降低的deg (OPRD1、CHL1和SLC2A2)。由于这些deg在胰岛细胞中的表达与在2型糖尿病患者胰岛中的表达不同,它们在胰岛素分泌中的实际作用有待进一步探讨。用大鼠克隆β细胞而不是用人胰岛进行的部分功能验证实验不能反映人胰岛的正常细胞环境。因此,尽管获得人胰岛有困难,但有必要观察这些基因的差异表达对人胰岛活性的影响。开发2型糖尿病预防干预和治疗的一个有吸引力的策略是筛选小分子化合物,并根据高希望基因的优先次序进行通知。Bacos等人。1证实PAX5过表达对葡萄糖刺激的胰岛素分泌具有特别强的抑制作用。PAX5是配对盒转录因子家族的一员,是淋巴细胞分化过程中确定b淋巴细胞谱系身份所必需的转录因子,在β-细胞中尚未研究。Bacos等人研究的PAX5对胰岛素分泌减弱作用的潜在机制包括线粒体功能受损和β细胞丢失。其他机制有待进一步探索。重要的是,生物信息学分析进一步表明,PAX5可能调节许多2型糖尿病相关的deg的转录,包括一些关键的deg,如SCL2A2。尽管如此,从2型糖尿病候选基因PAX5的发现中衍生出的多种假设应该被检验,以潜在地为精确治疗的发展提供信息。到目前为止,分析主要考虑了与其他基因和环境因素的影响分离的个体deg的影响。PAX5基因显示出高患病率的体细胞突变,在少数情况下观察到改变4。因此,在啮齿动物和人类研究中,将注意力转向阐明基因-基因和基因-环境相互作用将是及时的。PAX5的作用应该在多种胰岛细胞类型(包括α、δ和PP细胞)中进行检验,而不是在β细胞作用变体中。此外,PAX5对外周组织(如肝脏、骨骼肌和脂肪组织)的影响应该得到澄清,这些组织在胰岛素抵抗的发展中很重要(图1)。它编码GLUT2(葡萄糖转运蛋白2),这是β-细胞中主要的葡萄糖转运蛋白。虽然在患有2型糖尿病的啮齿动物中,SCL2A2表达对葡萄糖刺激的胰岛素分泌功能的影响已经得到了很好的证实,但在人类胰岛中,SCL2A2的表达是否参与一直存在争议。Bacos等人。1提供的证据表明,SCL2A2也可能在人类胰岛的胰岛素分泌中发挥重要作用。值得注意的是,不能排除DEGs在2型糖尿病胰岛中的潜在作用,其操作不改变β细胞数量或胰岛素分泌功能。这些基因对其他代谢缺陷的影响有待进一步研究。此外,Bacos等人也报道了许多deg。 1种与2型糖尿病密切相关,但尚未在功能上得到证实。在未来的研究中,应该对排名靠前的商学院以外的商学院进行考察。Bacos等人的工作为深入了解2型糖尿病的病理生理和解码2型糖尿病相关的转录组变化提供了宝贵的资源,这些变化是胰岛β细胞胰岛素分泌功能衰退的基础。这些发现为未来基于基因组的2型糖尿病的预测、预防和治疗提供了新的见解。值得注意的是,基因表达变化影响胰岛病理生理的机制仍有待阐明,这些变化的临床意义应审慎评估。作者声明无利益冲突。洪天培
{"title":"Delineating the transcriptional atlas for impaired insulin secretion: A window into type 2 diabetes pathophysiology","authors":"Jian Li,&nbsp;Jin Yang,&nbsp;Tianpei Hong","doi":"10.1111/jdi.14060","DOIUrl":"10.1111/jdi.14060","url":null,"abstract":"<p>Impaired insulin secretion from pancreatic islet β-cells is a major cause of metabolic dysregulation and type 2 diabetes mellitus. Complete transcriptomic characterization of islets in patients with type 2 diabetes mellitus has yet to be completed, and it remains challenging to link insulin secretion dysfunction with precise changes in gene expression. There are several ongoing initiatives aimed at enabling the discovery of regulatory molecules that might contribute to insulin secretion dysfunction and whole-body glucose homeostasis impairment. In one such line of research, Bacos <i>et al</i>.<span><sup>1</sup></span> obtained evidence suggesting that the gene <i>PAX5</i> might play an important role in impaired insulin secretion in human islets (Figure 1).</p><p>Given the established differences between mouse and human islets, type 2 diabetes mellitus candidate genes that were identified in mice might not have the same regulative effects on human islets. There is an unmet need for powerful transcriptomic analyses that can be applied to human islets isolated from individuals with type 2 diabetes mellitus and nondiabetic controls. Due to the difficulties associated with obtaining human islets, most human islet transcriptomic studies thus far have involved small cohorts and have lacked functional validation. Bacos <i>et al</i>.<span><sup>1</sup></span> generated a ribonucleic acid sequencing (RNA-Seq) resource bank from the large Lund University Diabetes Center pancreatic islet cohort. It is one of the largest existing type 2 diabetes mellitus human islet cohorts in existence, providing an extensive gene expression resource based on 309 islet preparations in total from individuals with type 2 diabetes mellitus and nondiabetic controls. They then identified 395 differentially expressed genes (DEGs) from the Lund University Diabetes Center cohort, and further performed some functional validation of DEGs <i>in vitro</i>.</p><p>The utility of transcriptomic resources can be affirmed by robust replication of DEGs across studies and databases. To date, few DEG replication studies in type 2 diabetes mellitus human islets have been reported, and the various studies in the literature showing replication have been relatively small, including the work by Bacos <i>et al</i>.<span><sup>1</sup></span> Unsurprisingly, the variance in demographic and pathophysiological profiles among sample donors affects DEG overlap across study cohorts. There remains a need to analyze human islets from a more diverse donor pool, and larger cohorts to clarify whether islet gene expression differs among individuals with type 2 diabetes mellitus in relation to demographic and pathophysiological variables. Another important factor affecting DEG overlap is the particular screen technology applied. RNA-Seq, microarray analysis and other screening technologies have been used to identify genes with altered expression in type 2 diabetes mellitus human islets, generating transcriptiona","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 11","pages":"1231-1233"},"PeriodicalIF":3.2,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14060","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A subtype of laminopathies: Generalized lipodystrophy-associated progeroid syndrome caused by LMNA gene c.29C>T mutation 层粘连蛋白病的一种亚型:LMNA基因c.29C>T突变引起的广泛性脂肪营养不良相关孕激素综合征
IF 3.2 3区 医学 Pub Date : 2023-07-13 DOI: 10.1111/jdi.14055
Shipeng Huang, Yan Zhang, Zuan Zhan, Shuhao Gong

The term laminopathies refers to a group of congenital diseases characterized by accelerated degeneration of human tissues. Mutations in LMNA, LMNB, ZMPSTE24, and other genes lead to structural and functional abnormalities associated with lamins. One subtype of laminopathy is the generalized lipodystrophy-associated progeroid syndrome (GLPS), which occurs in patients with heterozygous mutations of the LMNA gene c.29C>T(p.T10I). This paper reports the first case of GLPS in China and compares the clinical features of other GLPS patients with literature reports. A 16-year-old male patient was treated for diabetic ketoacidosis, presenting with premature aging appearance, systemic lipodystrophy, severe fatty liver, and decreased bone density. After peripheral blood DNA extraction and second-generation sequencing, a heterozygous mutation of exon 1 of the LMNA gene c.29C>T(p.T10I) was detected. This case of GLPS may provide a diagnostic and therapeutic basis for potential patients.

层粘连症是指一组以人体组织加速退化为特征的先天性疾病。LMNA、LMNB、ZMPSTE24和其他基因的突变导致与层粘连蛋白相关的结构和功能异常。层粘连病的一种亚型是广泛性脂肪营养不良相关的孕激素综合征(GLPS),其发生在LMNA基因c.29C>;T(p.T10I)。本文报道了中国首例GLPS患者,并将其他GLPS患者的临床特征与文献报道进行了比较。一名16岁男性患者接受糖尿病酮症酸中毒治疗,表现为早衰、全身性脂肪营养不良、严重脂肪肝和骨密度下降。在外周血DNA提取和第二代测序后,LMNA基因c.29C>;检测到T(第T10I页)。这种GLPS病例可能为潜在患者提供诊断和治疗基础。
{"title":"A subtype of laminopathies: Generalized lipodystrophy-associated progeroid syndrome caused by LMNA gene c.29C>T mutation","authors":"Shipeng Huang,&nbsp;Yan Zhang,&nbsp;Zuan Zhan,&nbsp;Shuhao Gong","doi":"10.1111/jdi.14055","DOIUrl":"https://doi.org/10.1111/jdi.14055","url":null,"abstract":"<p>The term laminopathies refers to a group of congenital diseases characterized by accelerated degeneration of human tissues. Mutations in LMNA, LMNB, ZMPSTE24, and other genes lead to structural and functional abnormalities associated with lamins. One subtype of laminopathy is the generalized lipodystrophy-associated progeroid syndrome (GLPS), which occurs in patients with heterozygous mutations of the LMNA gene c.29C&gt;T(p.T10I). This paper reports the first case of GLPS in China and compares the clinical features of other GLPS patients with literature reports. A 16-year-old male patient was treated for diabetic ketoacidosis, presenting with premature aging appearance, systemic lipodystrophy, severe fatty liver, and decreased bone density. After peripheral blood DNA extraction and second-generation sequencing, a heterozygous mutation of exon 1 of the LMNA gene c.29C&gt;T(p.T10I) was detected. This case of GLPS may provide a diagnostic and therapeutic basis for potential patients.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 10","pages":"1221-1225"},"PeriodicalIF":3.2,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14055","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41081519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Validity of the short-form five-item Problem Area in Diabetes questionnaire as a depression screening tool in type 2 diabetes mellitus patients 糖尿病五题问卷作为2型糖尿病患者抑郁筛查工具的有效性
IF 3.2 3区 医学 Pub Date : 2023-07-06 DOI: 10.1111/jdi.14051
Donovan Tay, Marvin Chua, Joan Khoo

Aims/Introduction

Depression is prevalent in diabetes patients and associated with poor outcomes, but is currently underdiagnosed, with no firm consensus on screening methods. We evaluated the validity of the short-form five-item Problem Areas in Diabetes (PAID-5) questionnaire as a screening tool for depression, comparing it with the Beck Depression Inventory-II (BDI-II) and nine-item Patient Health Questionnaire (PHQ-9).

Materials and Methods

A total of 208 English-speaking adults with type 2 diabetes, recruited from outpatient clinics, completed the BDI-II, PHQ-9 and PAID-5 questionnaires in English. Cronbach's α was used for internal reliability. Convergent validity was examined with BDI-II and PHQ-9. Receiver operating characteristics analyses were used to identify optimal PAID-5 cut-offs for the diagnosis of depression.

Results

All three screening tools were highly reliable, with BDI-II, PHQ-9 and PAID-5 having a Cronbach's α of 0.910, 0.870 and 0.940, respectively. There was a good correlation between BDI-II and PHQ-9, with a correlation co-efficient (r) of 0.73; and a moderate correlation between PAID-5 and PHQ-9, and PAID-5 and BDI-II, with r of 0.55 and 0.55 respectively (P values <0.01). An optimal PAID-5 cut-off ≥9 corresponded to both a BDI-II cut-off >14 (sensitivity 72%, specificity 784%, area under the curve 0.809) and a PHQ-9 cut-off >10 (sensitivity 84%, specificity 74%, area under the curve 0.806). Using a PAID-5 cut-off ≥9, the prevalence of depressive symptoms was 36.1%.

Conclusions

Depressive symptoms are prevalent in people with type 2 diabetes, with the degree of distress significantly related to the severity of depressive symptoms. PAID-5 is a valid and reliable screening tool, and a score ≥9 could prompt further confirmation for depression.

抑郁症在糖尿病患者中普遍存在,且与不良预后相关,但目前尚未得到充分诊断,在筛查方法上尚无坚定的共识。我们评估了简短的五项糖尿病问题领域问卷(PAID-5)作为抑郁症筛查工具的有效性,并将其与贝克抑郁量表- ii (BDI-II)和九项患者健康问卷(PHQ-9)进行了比较。材料与方法从门诊招募208例英语为母语的成人2型糖尿病患者,用英语填写BDI-II、PHQ-9和PAID-5问卷。内部信度采用Cronbach’s α。采用BDI-II和PHQ-9检测收敛效度。受试者工作特征分析用于确定抑郁症诊断的最佳PAID-5截止值。结果3种筛选工具均具有较高的可靠性,其中BDI-II、PHQ-9和PAID-5的Cronbach′s α分别为0.910、0.870和0.940。BDI-II与PHQ-9相关性较好,相关系数(r)为0.73;pai -5与PHQ-9、pai -5与BDI-II呈正相关,r分别为0.55和0.55 (P值<0.01)。最佳PAID-5临界值≥9对应于BDI-II的临界值>14(灵敏度72%,特异性784%,曲线下面积0.809)和PHQ-9的临界值>10(灵敏度84%,特异性74%,曲线下面积0.806)。采用PAID-5临界值≥9,抑郁症状的患病率为36.1%。结论2型糖尿病患者普遍存在抑郁症状,且抑郁程度与抑郁症状严重程度显著相关。pay -5是有效可靠的筛查工具,得分≥9分可提示进一步确认抑郁。
{"title":"Validity of the short-form five-item Problem Area in Diabetes questionnaire as a depression screening tool in type 2 diabetes mellitus patients","authors":"Donovan Tay,&nbsp;Marvin Chua,&nbsp;Joan Khoo","doi":"10.1111/jdi.14051","DOIUrl":"https://doi.org/10.1111/jdi.14051","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Depression is prevalent in diabetes patients and associated with poor outcomes, but is currently underdiagnosed, with no firm consensus on screening methods. We evaluated the validity of the short-form five-item Problem Areas in Diabetes (PAID-5) questionnaire as a screening tool for depression, comparing it with the Beck Depression Inventory-II (BDI-II) and nine-item Patient Health Questionnaire (PHQ-9).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A total of 208 English-speaking adults with type 2 diabetes, recruited from outpatient clinics, completed the BDI-II, PHQ-9 and PAID-5 questionnaires in English. Cronbach's α was used for internal reliability. Convergent validity was examined with BDI-II and PHQ-9. Receiver operating characteristics analyses were used to identify optimal PAID-5 cut-offs for the diagnosis of depression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All three screening tools were highly reliable, with BDI-II, PHQ-9 and PAID-5 having a Cronbach's α of 0.910, 0.870 and 0.940, respectively. There was a good correlation between BDI-II and PHQ-9, with a correlation co-efficient (<i>r</i>) of 0.73; and a moderate correlation between PAID-5 and PHQ-9, and PAID-5 and BDI-II, with <i>r</i> of 0.55 and 0.55 respectively (<i>P</i> values &lt;0.01). An optimal PAID-5 cut-off ≥9 corresponded to both a BDI-II cut-off &gt;14 (sensitivity 72%, specificity 784%, area under the curve 0.809) and a PHQ-9 cut-off &gt;10 (sensitivity 84%, specificity 74%, area under the curve 0.806). Using a PAID-5 cut-off ≥9, the prevalence of depressive symptoms was 36.1%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Depressive symptoms are prevalent in people with type 2 diabetes, with the degree of distress significantly related to the severity of depressive symptoms. PAID-5 is a valid and reliable screening tool, and a score ≥9 could prompt further confirmation for depression.</p>\u0000 </section>\u0000 </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 9","pages":"1128-1135"},"PeriodicalIF":3.2,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14051","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5728989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Contribution of animal models to diabetes research: Its history, significance, and translation to humans 动物模型对糖尿病研究的贡献:历史、意义和对人类的转化
IF 3.2 3区 医学 Pub Date : 2023-07-03 DOI: 10.1111/jdi.14034
Soroku Yagihashi

Diabetes mellitus is still expanding globally and is epidemic in developing countries. The combat of this plague has caused enormous economic and social burdens related to a lowered quality of life in people with diabetes. Despite recent significant improvements of life expectancy in patients with diabetes, there is still a need for efforts to elucidate the complexities and mechanisms of the disease processes to overcome this difficult disorder. To this end, the use of appropriate animal models in diabetes studies is invaluable for translation to humans and for the development of effective treatment. In this review, a variety of animal models of diabetes with spontaneous onset in particular will be introduced and discussed for their implication in diabetes research.

糖尿病仍在全球范围内蔓延,并在发展中国家流行。与这一瘟疫的斗争造成了与糖尿病患者生活质量下降有关的巨大经济和社会负担。尽管最近糖尿病患者的预期寿命显著改善,但仍需要努力阐明疾病过程的复杂性和机制,以克服这一困难的疾病。为此,在糖尿病研究中使用适当的动物模型对于转化为人类和开发有效的治疗方法是非常宝贵的。在这篇综述中,我们将介绍各种各样的糖尿病动物模型,特别是自发性发作的糖尿病动物模型,并讨论它们在糖尿病研究中的意义。
{"title":"Contribution of animal models to diabetes research: Its history, significance, and translation to humans","authors":"Soroku Yagihashi","doi":"10.1111/jdi.14034","DOIUrl":"https://doi.org/10.1111/jdi.14034","url":null,"abstract":"<p>Diabetes mellitus is still expanding globally and is epidemic in developing countries. The combat of this plague has caused enormous economic and social burdens related to a lowered quality of life in people with diabetes. Despite recent significant improvements of life expectancy in patients with diabetes, there is still a need for efforts to elucidate the complexities and mechanisms of the disease processes to overcome this difficult disorder. To this end, the use of appropriate animal models in diabetes studies is invaluable for translation to humans and for the development of effective treatment. In this review, a variety of animal models of diabetes with spontaneous onset in particular will be introduced and discussed for their implication in diabetes research.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 9","pages":"1015-1037"},"PeriodicalIF":3.2,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6102867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
miR-31 ameliorates type 2 diabetic vascular damage through up-regulation of hypoxia-inducible factor-1α/vascular endothelial growth factor-A miR-31通过上调缺氧诱导因子-1α/血管内皮生长因子- a改善2型糖尿病血管损伤
IF 3.2 3区 医学 Pub Date : 2023-07-02 DOI: 10.1111/jdi.14039
Yuan Fu, Ruochen Du, Yufei Wang, Yitong Yuan, Yujuan Zhang, Chunfang Wang, Xuanping Zhang

Aims

microRNA may be a new therapeutic direction for diabetes. As a typical tumor marker, miR-31 is involved in a variety of metabolic diseases, but the specific role is still unclear. This study aimed to investigate the effect of miR-31 on type 2 diabetes mellitus and its accompanying vascular injury, as well as on the effects of hypoxia-inducible factor-1α inhibitor (HIF1AN), hypoxia-inducible factor (HIF)-1α, and vascular endothelial growth factor (VEGF)-A expression in vitro and in vivo.

Materials and Methods

In vitro, a model of high-fat and high-glucose-induced human aortic endothelial cell (HAEC) injury was established to simulate diabetes mellitus (DM). Cell functions were compared between the control group, the DM damage group, and the group transfected with miR-31 after DM damage. In vivo, overexpressing miR-31 FVB mice and FVB mice were divided into the control and induced type 2 diabetes mellitus groups. Type 2 diabetes mellitus models were induced by a high-fat diet combined with streptozotocin. The lipid metabolism levels, viscera, and vascular damage were compared between the control and type 2 diabetes mellitus groups.

Results

In vitro, miR-31 improved the proliferation ability of damaged cells by targeting HIF1AN and up-regulating the expression of HIF-1α and VEGF-A. In vivo, miR-31 ameliorated the development of type 2 diabetes mellitus, disturbance of glucose and lipid metabolism, and damage to some organs. Meanwhile, miR-31 had a protective effect on vascular damage complicated by type 2 diabetes mellitus by increasing the levels of HIF-1α and VEGF-A.

Conclusion

Our experiments show that miR-31 can delay the progression of type 2 diabetes mellitus and ameliorate diabetic vascular injury.

目的:微rna可能是糖尿病治疗的新方向。miR-31作为一种典型的肿瘤标志物,参与多种代谢性疾病,但具体作用尚不清楚。本研究旨在探讨miR-31对2型糖尿病及其伴随血管损伤的影响,以及在体外和体内对缺氧诱导因子-1α抑制剂(HIF1AN)、缺氧诱导因子(HIF)-1α、血管内皮生长因子(VEGF)-A表达的影响。材料与方法体外建立高脂高糖诱导的人主动脉内皮细胞(HAEC)损伤模型,模拟糖尿病(DM)。比较对照组、DM损伤组和DM损伤后转染miR-31组的细胞功能。在体内,将过表达miR-31的FVB小鼠和FVB小鼠分为对照组和诱导型2型糖尿病组。采用高脂饮食联合链脲佐菌素诱导2型糖尿病模型。比较对照组和2型糖尿病组的脂质代谢水平、脏器和血管损伤情况。结果在体外,miR-31通过靶向HIF1AN,上调HIF-1α和VEGF-A的表达,提高受损细胞的增殖能力。在体内,miR-31改善了2型糖尿病的发展、糖脂代谢紊乱以及一些器官的损伤。同时,miR-31通过提高HIF-1α和VEGF-A水平对2型糖尿病并发血管损伤具有保护作用。结论miR-31可以延缓2型糖尿病的进展,改善糖尿病血管损伤。
{"title":"miR-31 ameliorates type 2 diabetic vascular damage through up-regulation of hypoxia-inducible factor-1α/vascular endothelial growth factor-A","authors":"Yuan Fu,&nbsp;Ruochen Du,&nbsp;Yufei Wang,&nbsp;Yitong Yuan,&nbsp;Yujuan Zhang,&nbsp;Chunfang Wang,&nbsp;Xuanping Zhang","doi":"10.1111/jdi.14039","DOIUrl":"https://doi.org/10.1111/jdi.14039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>microRNA may be a new therapeutic direction for diabetes. As a typical tumor marker, miR-31 is involved in a variety of metabolic diseases, but the specific role is still unclear. This study aimed to investigate the effect of miR-31 on type 2 diabetes mellitus and its accompanying vascular injury, as well as on the effects of hypoxia-inducible factor-1α inhibitor (HIF1AN), hypoxia-inducible factor (HIF)-1α, and vascular endothelial growth factor (VEGF)-A expression <i>in vitro</i> and <i>in vivo</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p><i>In vitro</i>, a model of high-fat and high-glucose-induced human aortic endothelial cell (HAEC) injury was established to simulate diabetes mellitus (DM). Cell functions were compared between the control group, the DM damage group, and the group transfected with miR-31 after DM damage. <i>In vivo</i>, overexpressing miR-31 FVB mice and FVB mice were divided into the control and induced type 2 diabetes mellitus groups. Type 2 diabetes mellitus models were induced by a high-fat diet combined with streptozotocin. The lipid metabolism levels, viscera, and vascular damage were compared between the control and type 2 diabetes mellitus groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>In vitro</i>, miR-31 improved the proliferation ability of damaged cells by targeting HIF1AN and up-regulating the expression of HIF-1α and VEGF-A. <i>In vivo</i>, miR-31 ameliorated the development of type 2 diabetes mellitus, disturbance of glucose and lipid metabolism, and damage to some organs. Meanwhile, miR-31 had a protective effect on vascular damage complicated by type 2 diabetes mellitus by increasing the levels of HIF-1α and VEGF-A.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our experiments show that miR-31 can delay the progression of type 2 diabetes mellitus and ameliorate diabetic vascular injury.</p>\u0000 </section>\u0000 </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 9","pages":"1070-1080"},"PeriodicalIF":3.2,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6089076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Non-classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease 非经典单核细胞频率与血清维生素 D3水平与周围动脉疾病相关的糖尿病足溃疡有关
IF 3.2 3区 医学 Pub Date : 2023-07-02 DOI: 10.1111/jdi.14048
Reham Hammad, Maisa A Abdel Wahab, Nehal Farouk, Mohamed Yahia Zakaria, Mona A Eldosoky, Asmaa A Elmadbouly, Sara A Tahoun, Eman Mahmoud, Seham K Khirala, Amena Rezk Mohammed, Wafaa Abdelaziz Emam, Asmaa A Abo Elqasem, Fatma M Kotb, Rasha Abd Elaziz Abd Elghany

Aims/Introduction

Peripheral artery disease (PAD) serves as a risk factor for diabetic foot ulcers (DFUs). PAD pathology involves atherosclerosis and impaired immunity. Non-classical monocytes are believed to have an anti-inflammatory role. 1,25-Dihydroxy vitamin D (vitamin D3) is claimed to have immune-modulating and lipid-regulating roles. Vitamin D receptor is expressed on monocytes. We aimed to investigate if circulating non-classical monocytes and vitamin D3 were implicated in DFUs associated with PAD.

Materials and Methods

There were two groups of DFU patients: group 1 (n = 40) included patients with first-degree DFUs not associated with PAD, and group 2 (n = 50) included patients with DFU with PAD. The monocyte phenotypes were detected using flow cytometry. Vitamin D3 was assessed by enzyme-linked immunosorbent assay.

Results

DFU patients with PAD showed a significant reduction in the frequency of non-classical monocytes and vitamin D3 levels, when compared with DFU patients without PAD. The percentage of non-classical monocytes positively correlated with vitamin D3 level (r = 0.4, P < 0.01) and high-density lipoprotein (r = 0.5, P < 0.001), whereas it was negatively correlated with cholesterol (r = −0.5, P < 0.001). Vitamin D3 was negatively correlated with triglyceride/high-density lipoprotein (r = −0.4, P < 0.01). Regression analysis showed that a high vitamin D3 serum level was a protective factor against PAD occurrence.

Conclusions

Non-classical monocytes frequency and vitamin D3 levels were significantly reduced in DFU patients with PAD. Non-classical monocytes frequency was associated with vitamin D3 in DFUs patients, and both parameters were linked to lipid profile. Vitamin D3 upregulation was a risk-reducing factor for PAD occurrence.

目的/简介外周动脉疾病(PAD)是糖尿病足溃疡(DFU)的危险因素。PAD病理涉及动脉粥样硬化和免疫受损。非经典单核细胞被认为具有抗炎作用。1,25-二羟基维生素 D(维生素 D3)声称具有免疫调节和脂质调节作用。维生素 D受体在单核细胞上表达。我们旨在研究循环中的非经典单核细胞和维生素 D3与PAD相关的DFU有关。材料与方法DFU患者分为两组: 1(n = 40)包括与PAD无关的一级DFU患者,以及 2(n = 50)包括患有PAD的DFU患者。单核细胞表型用流式细胞仪检测。维生素 D3通过酶联免疫吸附测定法进行评估。结果患有PAD的DFU患者的非经典单核细胞和维生素的频率显著降低 D3水平。非经典单核细胞的百分比与维生素呈正相关 D3水平(r = 0.4,P <; 0.01)和高密度脂蛋白(r = 0.5,P <; 0.001),而与胆固醇呈负相关(r = −0.5,P <; 0.001)。维生素 D3与甘油三酯/高密度脂蛋白呈负相关(r = −0.4,P <; 0.01)。回归分析表明 血清D3水平是防止PAD发生的保护因素。结论非经典单核细胞频率与维生素 患有PAD的DFU患者的D3水平显著降低。非经典单核细胞频率与维生素有关 D3,并且这两个参数都与脂质分布有关。维生素 D3上调是PAD发生的风险降低因素。
{"title":"Non-classical monocytes frequency and serum vitamin D3 levels are linked to diabetic foot ulcer associated with peripheral artery disease","authors":"Reham Hammad,&nbsp;Maisa A Abdel Wahab,&nbsp;Nehal Farouk,&nbsp;Mohamed Yahia Zakaria,&nbsp;Mona A Eldosoky,&nbsp;Asmaa A Elmadbouly,&nbsp;Sara A Tahoun,&nbsp;Eman Mahmoud,&nbsp;Seham K Khirala,&nbsp;Amena Rezk Mohammed,&nbsp;Wafaa Abdelaziz Emam,&nbsp;Asmaa A Abo Elqasem,&nbsp;Fatma M Kotb,&nbsp;Rasha Abd Elaziz Abd Elghany","doi":"10.1111/jdi.14048","DOIUrl":"https://doi.org/10.1111/jdi.14048","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Peripheral artery disease (PAD) serves as a risk factor for diabetic foot ulcers (DFUs). PAD pathology involves atherosclerosis and impaired immunity. Non-classical monocytes are believed to have an anti-inflammatory role. 1,25-Dihydroxy vitamin D (vitamin D<sub>3</sub>) is claimed to have immune-modulating and lipid-regulating roles. Vitamin D receptor is expressed on monocytes. We aimed to investigate if circulating non-classical monocytes and vitamin D<sub>3</sub> were implicated in DFUs associated with PAD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>There were two groups of DFU patients: group 1 (<i>n</i> = 40) included patients with first-degree DFUs not associated with PAD, and group 2 (<i>n</i> = 50) included patients with DFU with PAD. The monocyte phenotypes were detected using flow cytometry. Vitamin D<sub>3</sub> was assessed by enzyme-linked immunosorbent assay.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>DFU patients with PAD showed a significant reduction in the frequency of non-classical monocytes and vitamin D<sub>3</sub> levels, when compared with DFU patients without PAD. The percentage of non-classical monocytes positively correlated with vitamin D<sub>3</sub> level (<i>r</i> = 0.4, <i>P</i> &lt; 0.01) and high-density lipoprotein (<i>r</i> = 0.5, <i>P</i> &lt; 0.001), whereas it was negatively correlated with cholesterol (<i>r</i> = −0.5, <i>P</i> &lt; 0.001). Vitamin D<sub>3</sub> was negatively correlated with triglyceride/high-density lipoprotein (<i>r</i> = −0.4, <i>P</i> &lt; 0.01). Regression analysis showed that a high vitamin D<sub>3</sub> serum level was a protective factor against PAD occurrence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Non-classical monocytes frequency and vitamin D<sub>3</sub> levels were significantly reduced in DFU patients with PAD. Non-classical monocytes frequency was associated with vitamin D<sub>3</sub> in DFUs patients, and both parameters were linked to lipid profile. Vitamin D<sub>3</sub> upregulation was a risk-reducing factor for PAD occurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 10","pages":"1192-1201"},"PeriodicalIF":3.2,"publicationDate":"2023-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41081848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Noninvasive evaluation of donor and native pancreases following simultaneous pancreas–kidney transplantation using positron emission tomography/computed tomography 正电子发射断层扫描/计算机断层扫描对胰肾联合移植后供体和本地胰腺的无创评估
IF 3.2 3区 医学 Pub Date : 2023-06-28 DOI: 10.1111/jdi.14045
Takaaki Murakami, Toshihiro Nakamura, Hiroyuki Fujimoto, Junji Fujikura, Yoichi Shimizu, Kanae K. Miyake, Daisuke Otani, Kentaro Sakaki, Sakura Kiyobayashi, Takayuki Anazawa, Yuji Nakamoto, Nobuya Inagaki

It is crucial to develop practical and noninvasive methods to assess the functional beta-cell mass in a donor pancreas, in which monitoring and precise evaluation is challenging. A patient with type 1 diabetes underwent noninvasive imaging following simultaneous kidney–pancreas transplantation with positron emission tomography/computed tomography (PET/CT) using an exendin-based probe, [18F]FB(ePEG12)12-exendin-4. Following transplantation, PET imaging with [18F]FB(ePEG12)12-exendin-4 revealed simultaneous and distinct accumulations in the donor and native pancreases. The pancreases were outlined at a reasonable distance from the surrounding organs using [18F]FB(ePEG12)12-exendin-4 whole-body maximum intensity projection and axial PET images. At 1 and 2 h after [18F]FB(ePEG12)12-exendin-4 administration, the mean standardized uptake values were 2.96 and 3.08, respectively, in the donor pancreas and 1.97 and 2.25, respectively, in the native pancreas. [18F]FB(ePEG12)12-exendin-4 positron emission tomography imaging allowed repeatable and quantitative assessment of beta-cell mass following simultaneous kidney–pancreas transplantation.

开发实用且无创的方法来评估供体胰腺中的功能性β细胞质量至关重要,在这种方法中,监测和精确评估是具有挑战性的。一名1型糖尿病患者在同时进行肾胰腺移植后,使用基于艾塞那丁的探针[18F]FB(ePEG12)12-艾塞那丁-4进行正电子发射断层扫描/计算机断层扫描(PET/CT),进行了无创成像。移植后,[18F]FB(ePEG12)12-外泌肽-4的PET成像显示供体和天然胰腺中同时存在不同的积聚。使用[18F]FB(ePEG12)12-exendin-4全身最大强度投影和轴向PET图像,在离周围器官合理距离处勾勒胰腺轮廓。在1和2 [18F]FB(ePEG12)12-外泌肽-4给药后h,供体胰腺的平均标准化摄取值分别为2.96和3.08,天然胰腺分别为1.97和2.25。[18F]FB(ePEG12)12-exendin-4正电子发射断层扫描成像允许对肾胰腺移植后的β细胞质量进行可重复的定量评估。
{"title":"Noninvasive evaluation of donor and native pancreases following simultaneous pancreas–kidney transplantation using positron emission tomography/computed tomography","authors":"Takaaki Murakami,&nbsp;Toshihiro Nakamura,&nbsp;Hiroyuki Fujimoto,&nbsp;Junji Fujikura,&nbsp;Yoichi Shimizu,&nbsp;Kanae K. Miyake,&nbsp;Daisuke Otani,&nbsp;Kentaro Sakaki,&nbsp;Sakura Kiyobayashi,&nbsp;Takayuki Anazawa,&nbsp;Yuji Nakamoto,&nbsp;Nobuya Inagaki","doi":"10.1111/jdi.14045","DOIUrl":"https://doi.org/10.1111/jdi.14045","url":null,"abstract":"<p>It is crucial to develop practical and noninvasive methods to assess the functional beta-cell mass in a donor pancreas, in which monitoring and precise evaluation is challenging. A patient with type 1 diabetes underwent noninvasive imaging following simultaneous kidney–pancreas transplantation with positron emission tomography/computed tomography (PET/CT) using an exendin-based probe, [<sup>18</sup>F]FB(ePEG12)12-exendin-4. Following transplantation, PET imaging with [<sup>18</sup>F]FB(ePEG12)12-exendin-4 revealed simultaneous and distinct accumulations in the donor and native pancreases. The pancreases were outlined at a reasonable distance from the surrounding organs using [<sup>18</sup>F]FB(ePEG12)12-exendin-4 whole-body maximum intensity projection and axial PET images. At 1 and 2 h after [<sup>18</sup>F]FB(ePEG12)12-exendin-4 administration, the mean standardized uptake values were 2.96 and 3.08, respectively, in the donor pancreas and 1.97 and 2.25, respectively, in the native pancreas. [<sup>18</sup>F]FB(ePEG12)12-exendin-4 positron emission tomography imaging allowed repeatable and quantitative assessment of beta-cell mass following simultaneous kidney–pancreas transplantation.</p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 10","pages":"1187-1191"},"PeriodicalIF":3.2,"publicationDate":"2023-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14045","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41082024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus 多学科团队评审对糖尿病患者多药治疗对策的有效性
IF 3.2 3区 医学 Pub Date : 2023-06-25 DOI: 10.1111/jdi.14046
Shohei Nishida, Takehiro Kato, Yuichi Hayashi, Shoya Yamada, Hironori Fujii, Michi Yamada, Nao Asai, Shinya Shimizu, Takashi Niwa, Hirotoshi Iihara, Sodai Kubota, Mayu Sakai, Yoshihiro Takahashi, Ken Takao, Masami Mizuno, Takuo Hirota, Ryo Kobayashi, Yukio Horikawa, Daisuke Yabe, Akio Suzuki

Aims/Introduction

Polypharmacy in diabetes patients is related to worse clinical outcomes. The aim of this study was to evaluate the usefulness of our countermeasure for polypharmacy, which combines a pharmacist check followed by a multidisciplinary team review in diabetic patients with polypharmacy.

Methods

A single-center, retrospective observational study was conducted at Gifu University Hospital. Study participants included diabetic patients taking six or more drugs on admission to the diabetes ward between July 2021 and June 2022. Drugs which were discontinued by the present countermeasure were examined, and the number of drugs being taken by each patient was compared between admission and discharge.

Results

102 of 308 patients were taking six or more drugs on admission. The drugs being taken by these patients were evaluated by pharmacists using a checklist for polypharmacy. Eighty-four drugs which were evaluated as inappropriate or potentially inappropriate medications by pharmacists were discontinued following the multidisciplinary team review. The median and mean number of drugs taken by the 102 patients significantly decreased from 9.0 (IQR: 8–12) and 9.26 ± 2.64 on admission to 9.0 (IQR: 6–10) and 8.42 ± 2.95 on discharge (P = 0.0002). We followed up with these patients after discontinuation of the drugs and confirmed that their clinical status had not deteriorated.

Conclusion

The present countermeasure for polypharmacy, which combines a pharmacist check based on a checklist for evaluating polypharmacy followed by a multidisciplinary team review, was useful for reducing the number of inappropriate or potentially inappropriate medications taken by diabetes patients with polypharmacy.

目的/简介糖尿病患者的多药治疗与较差的临床结果有关。本研究的目的是评估我们的多药对策的有效性,该对策结合了药剂师检查和多学科团队对糖尿病多药患者的审查。方法在岐阜大学医院进行单中心回顾性观察研究。研究参与者包括2021年7月至2022年6月期间入住糖尿病病房时服用六种或六种以上药物的糖尿病患者。检查了因本对策而停用的药物,并比较了每位患者在入院和出院期间服用的药物数量。结果308例患者中有102例在入院时服用了6种或6种以上药物。药剂师使用多药对照表对这些患者服用的药物进行了评估。在多学科团队审查后,药剂师评估为不合适或潜在不合适药物的84种药物被停用。102名患者服用药物的中位数和平均数从9.0(IQR:8-12)和9.26显著下降 ± 入院时为2.64(IQR:6-10)和8.42 ± 2.95出院时(P = 0.0002)。我们在停药后对这些患者进行了随访,并确认他们的临床状况没有恶化。结论目前的多药治疗对策是,在评估多药治疗的检查表的基础上进行药剂师检查,然后进行多学科团队审查,这有助于减少糖尿病多药患者服用不适当或潜在不适当药物的数量。
{"title":"Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitus","authors":"Shohei Nishida,&nbsp;Takehiro Kato,&nbsp;Yuichi Hayashi,&nbsp;Shoya Yamada,&nbsp;Hironori Fujii,&nbsp;Michi Yamada,&nbsp;Nao Asai,&nbsp;Shinya Shimizu,&nbsp;Takashi Niwa,&nbsp;Hirotoshi Iihara,&nbsp;Sodai Kubota,&nbsp;Mayu Sakai,&nbsp;Yoshihiro Takahashi,&nbsp;Ken Takao,&nbsp;Masami Mizuno,&nbsp;Takuo Hirota,&nbsp;Ryo Kobayashi,&nbsp;Yukio Horikawa,&nbsp;Daisuke Yabe,&nbsp;Akio Suzuki","doi":"10.1111/jdi.14046","DOIUrl":"https://doi.org/10.1111/jdi.14046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims/Introduction</h3>\u0000 \u0000 <p>Polypharmacy in diabetes patients is related to worse clinical outcomes. The aim of this study was to evaluate the usefulness of our countermeasure for polypharmacy, which combines a pharmacist check followed by a multidisciplinary team review in diabetic patients with polypharmacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A single-center, retrospective observational study was conducted at Gifu University Hospital. Study participants included diabetic patients taking six or more drugs on admission to the diabetes ward between July 2021 and June 2022. Drugs which were discontinued by the present countermeasure were examined, and the number of drugs being taken by each patient was compared between admission and discharge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>102 of 308 patients were taking six or more drugs on admission. The drugs being taken by these patients were evaluated by pharmacists using a checklist for polypharmacy. Eighty-four drugs which were evaluated as inappropriate or potentially inappropriate medications by pharmacists were discontinued following the multidisciplinary team review. The median and mean number of drugs taken by the 102 patients significantly decreased from 9.0 (IQR: 8–12) and 9.26 ± 2.64 on admission to 9.0 (IQR: 6–10) and 8.42 ± 2.95 on discharge (<i>P</i> = 0.0002). We followed up with these patients after discontinuation of the drugs and confirmed that their clinical status had not deteriorated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The present countermeasure for polypharmacy, which combines a pharmacist check based on a checklist for evaluating polypharmacy followed by a multidisciplinary team review, was useful for reducing the number of inappropriate or potentially inappropriate medications taken by diabetes patients with polypharmacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 10","pages":"1202-1208"},"PeriodicalIF":3.2,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41082161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls 血管紧张素受体-奈普利素抑制剂在临床糖尿病管理中的影响:潜在的益处和缺陷
IF 3.2 3区 医学 Pub Date : 2023-06-25 DOI: 10.1111/jdi.14044
Tomoko Kato, Takaaki Murakami, Daisuke Yabe, Norio Harada

The possible mechanism of increased urinary C-peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C-peptides in the kidney and thus increase the urinary C-peptide level.

研究了尿c肽升高的可能机制。Neprilysin抑制可阻断利钠肽的降解,并引起利钠和降压作用。抑制Neprilysin可能类似地阻断肾中c肽的降解,从而增加尿c肽水平。
{"title":"Impact of the angiotensin receptor-neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls","authors":"Tomoko Kato,&nbsp;Takaaki Murakami,&nbsp;Daisuke Yabe,&nbsp;Norio Harada","doi":"10.1111/jdi.14044","DOIUrl":"https://doi.org/10.1111/jdi.14044","url":null,"abstract":"<p>The possible mechanism of increased urinary C-peptide due to neprilysin inhibitors is investigated. Neprilysin inhibition blocks degradation of natriuretic peptides, and elicits a natriuretic and antihypertensive effect. Neprilysin inhibition might similarly block degradation of C-peptides in the kidney and thus increase the urinary C-peptide level.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":190,"journal":{"name":"Journal of Diabetes Investigation","volume":"14 9","pages":"1038-1040"},"PeriodicalIF":3.2,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.14044","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6038421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Diabetes Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1